189 related articles for article (PubMed ID: 37791224)
21. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Sheikh S; Lebel E; Trudel S
Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
[TBL] [Abstract][Full Text] [Related]
22. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
[TBL] [Abstract][Full Text] [Related]
23. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
25. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
26. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
27. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A; Bobin A; Tabone L; Lambert J; Boccaccio C; Deal C; Petillon MO; Allangba O; Agape P; Arnautou P; Belkhir R; Cailleres S; Chaoui D; Chrétien ML; Decaux O; Schulmann S; Frenzel L; Gastaud L; Huart A; Hulin C; Karlin L; Laribi K; Le Calloch R; Lenain P; Macro M; Manier S; Montes L; Moreau S; Moreau P; Morel V; Norwood J; Piocelle FO; Perrot A; Pica GM; Rey P; Schmitt A; Stoppa AM; Tiab M; Touzeau C; Vidal V; Vignon M; Vincent L; Van De Wyngaert Z; Zarnitsky C; Kerbouche N; Paka P; Leleu X; Arnulf B; Avet-Loiseau H; Du Myélome IIF
Haematologica; 2023 Oct; 108(10):2774-2782. PubMed ID: 37078253
[TBL] [Abstract][Full Text] [Related]
28. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
[TBL] [Abstract][Full Text] [Related]
29. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
[TBL] [Abstract][Full Text] [Related]
30. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
[TBL] [Abstract][Full Text] [Related]
31. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
Jewell RC; Mills RJ; Farrell C; Visser SAG
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38924122
[TBL] [Abstract][Full Text] [Related]
32. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
33. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
[TBL] [Abstract][Full Text] [Related]
34. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R; Lonial S; Voorhees PM; Esposti SD; Gorsh B; Gupta I; Opalinska J; Sapra S; Piontek T; He Z; Kleinman D; Schaumberg D; Regnault A; Meunier J; Eliason L
J Adv Pract Oncol; 2023 Sep; 14(6):503-518. PubMed ID: 37808071
[TBL] [Abstract][Full Text] [Related]
35. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
36. Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.
Gil-Sierra MD; Briceño-Casado MDP; Julia-Luna FJ; Martinez-Moya MD
Indian J Pharmacol; 2022; 54(5):373-376. PubMed ID: 36537407
[TBL] [Abstract][Full Text] [Related]
37. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
[TBL] [Abstract][Full Text] [Related]
39. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Joseph NS; Tai YT; Anderson KC; Lonial S
Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
[TBL] [Abstract][Full Text] [Related]
40. Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin.
Lu R; Morphey A; Diaz F; Chen J; Razmandi A; Richards T
J Adv Pract Oncol; 2023 May; 14(4):300-306. PubMed ID: 37313276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]